Kaplan–Meier analyses of 703 glioma patients in TCGA revealed that while expression of RIPK1, RIPK3, and MLKL did not correlate with OS in grade II tumors, high expression of each was associated with significantly reduced OS in grade III gliomas (HR = 2.03, p = 0.002; HR = 2.09, p = 0.002; HR = 2.10, p = 0.001, respectively) (Fig. S4A–C). The gene discussed is RIPK1; the disease is central nervous system cancer.